Leachim (Travoprost)

Travoprost binds to prostaglandin F2α (FP) receptors in the eye, stimulating the uveoscleral outflow pathway. This increased drainage of aqueous humor reduces intra‑ocular pressure, which is the primary therapeutic goal in glaucoma and ocular hypertension management.

The prescribed dose of travoprost is determined by the treating ophthalmologist. Typically, one drop is instilled into the affected eye(s) once daily in the evening, but the exact regimen should follow the clinician’s instructions and the product label.

Safety data for travoprost in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order Leachim, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Travoprost and latanoprost belong to the same prostaglandin analog class and share a similar mechanism of increasing uveoscleral outflow. Clinical studies show comparable efficacy in lowering intra‑ocular pressure, though individual patient response and tolerability may differ, making physician selection based on patient‑specific factors.

Leachim should be stored at room temperature, below 25 °C, in its original packaging. Protect the bottle from moisture and direct sunlight. Do not freeze the product, and keep the dropper tip clean to avoid contamination.

Leachim is administered as an ocular drop. The patient should wash hands, tilt the head back, pull down the lower eyelid to create a pocket, and place a single drop into the conjunctival sac of the affected eye(s). Close the eye gently for a few seconds and avoid blinking excessively.

Serious risks associated with travoprost include uveitis, cystoid macular edema, severe allergic reactions, and sudden vision loss due to uncontrolled pressure spikes. Patients should report any sudden eye pain, redness, vision changes, or swelling to their eye care professional immediately.

Travoprost is contraindicated in patients with known hypersensitivity to travoprost or any component of the formulation, and in eyes with active inflammation, infection, or severe ocular surface disease. Caution is also advised for individuals with a history of herpetic eye disease.